Cyclacel Pharmaceuticals, Inc. Company Review & Valuation
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.
The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors.
In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage.
Cyclacel Pharmaceuticals, Inc.
was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.